Running for the fifth year in a row, the EIT Health Catapult is one of 23 accelerator initiatives run by EIT Health in 2020 to raise a new generation of companies into a position where they are able to deliver solutions that can improve the lives of patients and citizens in Europe. The programme boosts the development of European start-ups in healthcare by exposing them to leading experts and international investors. Prizes of €40,000 (for first place), €20,000 (for second place) and €10,000 (for third place) are awarded to three winners in each of the categories: biotech, medtech and digital, as well as €800,000 in in-kind support from sponsors including Nasdaq, Amazon Web Services, L3S Partnership, Virdis Group, Lallianse and McDermott Will & Emery. The three-stage process, taking place over a period of one year, came to an end last week when the nine winning start-ups were announced at the final day of the EIT Health Summit.
Here are the winners:
Digital health category
‘Methinks AI’ took first place for its solution of using imaging technology to reduce time to treatment in stroke patients where every second counts. ‘Popit’ took second place for its sensor technology to improve patients’ adherence to medicines, and ‘PatchAI’ was awarded third place for its digital solution to improve compliance in clinical trials.
‘New Born Solutions’ was awarded first place for its solution to improve the detection of infectious diseases such as meningitis in new-borns. ‘STIL’ came in second place for its solution to reduce tremour in patients such as those with Parkinson’s disease, and Gradient was awarded third place for its minimally invasive product to treat pulmonary hypertension.
‘UVera’ was awarded first place (as well as the Alex Casta Audience Award, which is voted on live by the EIT Health Catapult audience during the EIT Health Summit) for its solution to provide natural, safe, potent, stable and eco-friendly UV protection. In second place was ‘PhagoMed’ whose solution uses a synthetic biology platform to precisely target any bacterial pathogen, and in third place was ‘Gelmetix’ who is developing bio-inductive gels that modify cell behaviour to treat patients suffering from chronic lower back pain and osteoarthritis.
We congratulate the DACH finalist PhagoMed for their achievement.
For more information about the EIT Health Catapult competition, and to apply for 2021 please visit eithealth.eu/catapult.